Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 981 to 990 of 1514 total matches.
Dupilumab (Dupixent) for Asthma
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019 (Issue 1563)
was effective irrespective of baseline blood
7
The Medical Letter ® Vol. 61 (1563) January 14, 2019 ...
The FDA has approved the subcutaneously injected
monoclonal antibody dupilumab (Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of
patients ≥12 years old with moderate to severe
asthma with an eosinophilic phenotype or with oral
corticosteroid-dependent asthma. Dupilumab was
approved earlier to treat adults with moderate to
severe atopic dermatitis inadequately controlled with
topical therapies.
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019 (Issue 1566)
of this material is strictly prohibited.
For further information call: 800-211-2769
27
The Medical Letter ® Vol ...
Since 2008, because of safety concerns, the FDA has
mandated that long-term cardiovascular outcomes trials
be conducted for all new drugs for type 2 diabetes.
Reductions in the incidence of macrovascular complications
in these trials with some sodium-glucose
co-transporter 2 (SGLT2) inhibitors and glucagon-like
peptide 1 (GLP-1) receptor agonists in patients at risk
for cardiovascular disease (see Table 1) have led to
new recommendations.
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
The Medical Letter ® Vol. 61 (1573) June 3, 2019
ADVERSE EFFECTS — In the 6 placebo-controlled
clinical ...
The FDA has approved the 5-HT4 receptor agonist
prucalopride (Motegrity – Shire) for treatment of chronic
idiopathic constipation (CIC) in adults. Prucalopride is
the only drug currently approved in the US for treatment
of CIC that stimulates colonic peristalsis. It has been
available in Europe and Canada for several years.
Colorectal Cancer Screening
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
or 2 first-degree relatives of any age.
98
The Medical Letter ® Vol. 61 (1575) July 1, 2019
than ...
Most colorectal cancers arise from localized
adenomatous polyps in a process that may take
10 years or more. Early detection and removal of
a precancerous colonic lesion (polyp) can prevent
cancer from developing.
Benzhydrocodone/Acetaminophen (Apadaz) for Pain
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
administration of 2 crushed tablets, hydrocodone
111
The Medical Letter ® Vol. 61 (1576) July 15, 2019 ...
The FDA has approved Apadaz (KemPharm), a short-acting,
fixed-dose combination of benzhydrocodone
and acetaminophen, for short-term management
(≤14 days) of acute pain severe enough to require an
opioid and for which alternative treatment options
are inadequate. Benzhydrocodone is a prodrug of
hydrocodone. Fixed-dose combinations of short-acting
hydrocodone and acetaminophen or ibuprofen
have been available for years and are the most abused
opioid products in the US. Apadaz was developed
under the presumption that inclusion of the inactive
prodrug would reduce the potential for...
Upadacitinib (Rinvoq) - A New JAK Inhibitor for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019 (Issue 1585)
,
have been reported in clinical trials.
184
The Medical Letter ® Vol. 61 (1585) November 18, 2019 ...
The FDA has approved upadacitinib (Rinvoq –
Abbvie), an oral Janus kinase (JAK) inhibitor, for
treatment of adults with moderately to severely
active rheumatoid arthritis (RA) who have had
an inadequate response to or cannot tolerate
methotrexate (Trexall, and others). Upadacitinib is
the third JAK inhibitor to be approved in the US for
treatment of RA; tofacitinib (Xeljanz, Xeljanz XR)
and baricitinib (Olumiant) were approved earlier.
Minocycline Foam (Amzeeq) for Acne
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
kg: 60 mg; 55-84 kg: 100 mg; 85-136 kg: 150 mg).
69
The Medical Letter ® Vol. 62 (1597) May 4, 2020 ...
The FDA has approved a 4% aerosol foam formulation
of minocycline (Amzeeq – Foamix) for topical
treatment of inflammatory lesions of non-nodular
moderate to severe acne in patients ≥9 years old. It is
the first topical tetracycline formulation to be approved
for use in patients with acne. Oral minocycline
(Minocin, Solodyn, and generics) is
Eptinezumab (Vyepti) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
. Neurology 2019; 92 (15 Suppl).
86
The Medical Letter ® Vol. 62 (1599) June 1, 2020
headaches in adults ...
The FDA has approved eptinezumab-jjmr (Vyepti –
Lundbeck), a calcitonin gene-related peptide (CGRP)
antagonist administered IV once every 3 months, for
migraine prevention in adults. It is the fourth monoclonal
antibody to be approved for this indication; erenumab
(Aimovig), fremanezumab (Ajovy), and galcanezumab
(Emgality), which are all given subcutaneously once
monthly (fremanezumab can also be given once every 3
months), were approved earlier.
Viloxazine ER (Qelbree) for ADHD
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
Letter ® Vol. 63 (1627) June 28, 2021
PREGNANCY AND LACTATION — Viloxazine was
associated with fetal ...
The FDA has approved viloxazine extended-release
capsules (Qelbree – Supernus) for treatment of
attention-deficit/hyperactivity disorder (ADHD) in
children 6-17 years old. Viloxazine is the second
selective norepinephrine reuptake inhibitor to be
approved in the US for treatment of ADHD; atomoxetine
(Strattera, and generics) was approved in 2002.
Ponesimod (Ponvory) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021 (Issue 1630)
to confirmed disability accumulation at 12 and
24 weeks.8
The Medical Letter ® Vol. 63 (1630) August 9, 2021 ...
The FDA has approved ponesimod (Ponvory –
Janssen), a sphingosine 1-phosphate (S1P) receptor
modulator, for treatment of adults with relapsing forms
of multiple sclerosis (MS), including clinically isolated
syndrome (initial neurological episode), relapsing-remitting
disease, and active secondary progressive
MS (SPMS). Ponesimod is the fourth oral S1P receptor
modulator to be approved in the US for once-daily
treatment of relapsing forms of MS; ozanimod
(Zeposia) and siponimod (Mayzent) are also approved
for use in adults, and fingolimod (Gilenya) is indicated
for use in patients...